Department of Pathology, Riga Stradins University, Riga, Latvia.
Respiratory Disease Clinic, University Hospital, Modena, Italy.
J Thorac Oncol. 2016 Apr;11(4):e49-51. doi: 10.1016/j.jtho.2015.12.096. Epub 2015 Dec 30.
The authors report two cases of epidermal growth factor receptor gene (EGFR)-mutant stage IV lung adenocarcinomas developing immunohistochemically proven squamous cell carcinoma (SCC) "transformation" concurrently with T790M EGFR mutation, leading to acquired resistance to EGFR inhibitors. Moreover, the histologic change of EGFR-mutant lung adenocarcinoma into SCC has been recently reported in literature. The histological transformation to SCC appears as a novel mechanism of acquired EGFR TKI resistance in EGFR-mutated adenocarcinomas and it may be challenging for treatment.
作者报告了两例表皮生长因子受体基因（EGFR）突变型 IV 期肺腺癌病例，这些病例同时发生了免疫组织化学证实的鳞状细胞癌（SCC）“转化”，伴有 T790M EGFR 突变，导致对 EGFR 抑制剂产生获得性耐药。此外，EGFR 突变型肺腺癌向 SCC 的组织学变化最近在文献中有所报道。EGFR 突变型腺癌对 EGFR TKI 获得性耐药的新机制似乎是 SCC 的组织学转化，这可能对治疗构成挑战。
